ArticleBMC medicine2015
Amyloid imaging for dementia in clinical practice.
Article in BMC medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 57 citations in OpenAlex.
- The Biomarker Profile of Alzheimer's Disease for Disease-Modifying Treatment Eligibility: Questions and Debates.International journal of molecular sciences · 2025Review
- How well do plasma Alzheimer's disease biomarkers reflect the CSF amyloid status?Journal of neurology, neurosurgery, and psychiatry · 2025Article
- Prospecting salivary tau as a diagnostic for Alzheimer's type dementia.Dementia & neuropsychologia · 2025Article
- Serum Lipoprotein Profiling by NMR Spectroscopy Reveals Alterations in HDL-1 and HDL-2 Apo-A2 Subfractions in Alzheimer's Disease.International journal of molecular sciences · 2024Article
- Serum metabolic signatures for Alzheimer's Disease reveal alterations in amino acid composition: a validation study.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- VasCog 2023: 20 years of research on vascular behavioural and cognitive disorders.Cerebral circulation - cognition and behavior · 2024Article
- Review
- Online clinical tools to support the use of new plasma biomarker diagnostic technology in the assessment of Alzheimer's disease: a narrative review.Brain communications · 2023Review
- Detection of Glial Fibrillary Acidic Protein in Patient Plasma Using On-Chip Graphene Field-Effect Biosensors, in Comparison with ELISA and Single-Molecule Array.ACS sensors · 2022Article
- Clinically oriented Alzheimer's biosensors: expanding the horizons towards point-of-care diagnostics and beyond.RSC advances · 2021Review
- Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.Alzheimer's research & therapy · 2020Article
- Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use.Journal of personalized medicine · 2020Review
- Molecular and Imaging Biomarkers in Alzheimer's Disease: A Focus on Recent Insights.Journal of personalized medicine · 2020Review
- High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.Neurology · 2019Article
- Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic.Nature reviews. Neurology · 2018Review
- Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018Article
- Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer's Disease.Neurology and therapy · 2017Review
- A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging.Alzheimer's & dementia (Amsterdam, Netherlands) · 2017Article
- Long-Term Storage Effects on Stability of AβDementia and geriatric cognitive disorders extraArticle
- Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In vivo imaging of brain amyloid using positron emission tomography (PET) scanning is widely used in research studies of dementia, with three amyloid PET ligands being licenced for clinical use. The main clinical use of PET is to help confirm or exclude the likely diagnosis of Alzheimer's disease in challenging cases, where diagnostic uncertainty remains after current clinical and investigative work up. Whilst diagnostically valuable in such select cases, much wider clinical adoption, especially for very early disease, will be limited by both cost and the lack of a currently effective disease-modifying treatment that requires such early case identification. The use of amyloid imaging to appropriately stratify subjects for prognostic studies and therapeutic trials should increase the efficiency and potentially shorten the time of such studies, and its use combined with other biomarkers and genetics will likely lead to new ways of defining and classifying the dementias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.